Although Sanofi delivered an earnings miss which still had encouraging results, SNY stock tanked, offering a potential ...

Sanofi reports strong Q2 2025 growth with innovative launches like Dupixent and strategic acquisitions boosting sales.

By the end of 2024, Axmed had partnered with over 20 organizations across 15 countries. It processed more than 4,200 orders, ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.0759 ET – Shares in European pharmaceutical companies are mostly ...

The remainder of 2025 will be busy for Vir Biotechnology as it strives to successfully pivot to developing cancer and infectious disease therapies.

The Pasteur Institute in Ho Chi Minh City and Nagasaki University of Japan, both leading facilities in tropical medicine and ...

Explore market-impacting Trump administration moves, from drug pricing reforms targeting pharma giants to Swiss tariff hikes.

US mRNA specialist Moderna has announced that the UK Court of Appeal has upheld the validity of its EP'949 patent.

The Clinical Advisor spoke with Audrey M. Stevenson, PhD, MPH, MSN, FNP-BC, about how the changes to ACIP will affect vaccination recommendations moving forward. Dr Stevenson is a faculty member of ...

US mRNA specialist Moderna has today reported financial results and provided business updates for the second quarter of 2025, ...

Sanofi missed analyst projections of $1.32 with Q2 earnings per share (EPS) of $1.25. Revenue was €9.89 billion, which was ...